Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C149H244N44O48S2 |
| Molecular Weight | 3483.928 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 33 / 33 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](NC(C)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC3=CC=C(O)C=C3)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(N)=O
InChI
InChIKey=KRSXWFQIZOXHPX-XTWYBNIISA-N
InChI=1S/C149H244N44O48S2/c1-67(2)48-89(180-143(236)115(73(13)14)188-140(233)103-65-243-242-64-102(166-79(20)200)139(232)185-100(62-195)137(230)179-96(56-109(155)205)134(227)177-93(52-71(9)10)132(225)184-101(63-196)138(231)191-118(78(19)199)146(239)186-103)121(214)161-60-111(207)167-83(28-21-23-43-150)122(215)174-92(51-70(7)8)131(224)183-99(61-194)136(229)171-86(37-40-106(152)202)124(217)169-88(39-42-112(208)209)125(218)176-91(50-69(5)6)130(223)178-94(54-81-58-159-66-163-81)133(226)168-84(29-22-24-44-151)123(216)175-90(49-68(3)4)129(222)170-87(38-41-107(153)203)127(220)190-117(77(18)198)145(238)182-98(53-80-33-35-82(201)36-34-80)148(241)193-47-27-32-105(193)141(234)172-85(30-25-45-160-149(157)158)126(219)189-116(76(17)197)144(237)181-97(57-113(210)211)135(228)187-114(72(11)12)142(235)162-59-110(206)164-74(15)120(213)173-95(55-108(154)204)128(221)165-75(16)147(240)192-46-26-31-104(192)119(156)212/h33-36,58,66-78,83-105,114-118,194-199,201H,21-32,37-57,59-65,150-151H2,1-20H3,(H2,152,202)(H2,153,203)(H2,154,204)(H2,155,205)(H2,156,212)(H,159,163)(H,161,214)(H,162,235)(H,164,206)(H,165,221)(H,166,200)(H,167,207)(H,168,226)(H,169,217)(H,170,222)(H,171,229)(H,172,234)(H,173,213)(H,174,215)(H,175,216)(H,176,218)(H,177,227)(H,178,223)(H,179,230)(H,180,236)(H,181,237)(H,182,238)(H,183,224)(H,184,225)(H,185,232)(H,186,239)(H,187,228)(H,188,233)(H,189,219)(H,190,220)(H,191,231)(H,208,209)(H,210,211)(H4,157,158,160)/t74-,75-,76+,77+,78+,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,114-,115-,116-,117-,118-/m0/s1
| Molecular Formula | C149H244N44O48S2 |
| Molecular Weight | 3483.928 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 33 / 33 |
| E/Z Centers | 23 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:52:37 GMT 2023
by
admin
on
Sat Dec 16 11:52:37 GMT 2023
|
| Record UNII |
Q91PJI8O7T
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
138454980
Created by
admin on Sat Dec 16 11:52:38 GMT 2023 , Edited by admin on Sat Dec 16 11:52:38 GMT 2023
|
PRIMARY | |||
|
1432581-36-6
Created by
admin on Sat Dec 16 11:52:37 GMT 2023 , Edited by admin on Sat Dec 16 11:52:37 GMT 2023
|
PRIMARY | |||
|
Q91PJI8O7T
Created by
admin on Sat Dec 16 11:52:38 GMT 2023 , Edited by admin on Sat Dec 16 11:52:38 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
In vitro, KBP-042 demonstrated superior binding affinity and activation of amylin and calcitonin receptors, and ex vivo, KBP-042 exerted inhibitory action on stimulated insulin and glucagon release from isolated islets. In vivo, KBP-042 induced a superior and pronounced reduction in food intake in conjunction with a sustained pair-fed corrected weight loss in DIO rats. Concomitantly, KBP-042 improved glucose homeostasis and reduced hyperinsulinemia and hyperleptinemia in conjunction with enhanced insulin sensitivity. In ZDF rats, KBP-042 induced a superior attenuation of diabetic hyperglycemia and alleviated impaired glucose and insulin tolerance. These results could provide the basis for oral KBP-042 as a novel therapeutic agent in type 2 diabetes.
|
||
|
ACTIVE MOIETY |
At the same time, s.c. KBP-042 suppressed the inappropriate glucagon response better than the oral formulation. Furthermore, KBP-042 was found to reduce incretins GLP-1 and GIP and considerably, improve gastric emptying, and to alleviate leptin resistance, as well as insulin resistance. In conclusion, the subcutaneous route of administration was found to have the same beneficial effects on blood glucose homeostasis and weight loss as well as resistance towards important insulin and leptin, albeit with a markedly lower variation in both exposure and biological responses. These data support the application of subcutaneously delivered peptide for mechanistic studies, and highlight the potential of developing s.c. KBP-042 as a therapy for T2D.
|
